About 57 people are diagnosed with breast cancer every day in Australia, with instances having grown over the past decade. New and improved treatments are crucial, and to address that, Australian diagnostics company INOVIQ (ASX: IIQ) has developed a special exosome therapy that can target and kill breast cancer cells in lab tests. The Company
Read More
In 2023, the emerging cancer diagnostics market is estimated to be valued at over $23 billion. Everything is fair game in “finding a cure to cancer”—be it potentially using blood drops or narrowing in on exosomes, which are tiny structures our cells produce to transfer messages, proteins, lipids, the good stuff. These structures might also
Read More
Precision diagnostics company INOVIQ (ASX: IIQ) has achieved noteworthy results from an independent clinical validation study of its SubB2M/CA15-3 test for breast cancer detection. The study has reported high accuracy (87%), sensitivity (81%), and specificity (93%) for the test, outperforming a leading approved CA15-3 test. INOVIQ CEO, Dr Leearne Hinch, said, “The outstanding results from
Read More
Treating cancer is a primary goal of many biotech companies, but for any treatment to begin, physicians need a definitive diagnosis. We know that time is critical in disease diagnosis and initiating treatment sooner translates to better patient outcomes more often than not. The field of diagnostics is the yin to medical treatment’s yang. They
Read More